The Location and Distribution of Transurethral Bulking Agent: 3-Dimensional Ultrasound Study

被引:10
作者
Yune, Junchan Joshua [1 ]
Quiroz, Lieschen [2 ]
Nihira, Mikio A. [2 ]
Siddighi, Sam [3 ]
O'Leary, Dena E. [2 ]
Santiago, A. [2 ]
Shobeiri, S. Abbas [2 ]
机构
[1] Loma Linda Univ, Female Pelv Med & Reconstruct Surg, Urol, Suite 1100,11370 Anderson St, Loma Linda, CA 92354 USA
[2] Univ Oklahoma, Hlth Sci, Female Pelv Med & Reconstruct Surg, Oklahoma City, OK USA
[3] Loma Linda Univ, Female Pelv Med & Reconstruct Surg, Gynecol & Obstet, Loma Linda, CA 92354 USA
来源
FEMALE PELVIC MEDICINE AND RECONSTRUCTIVE SURGERY | 2016年 / 22卷 / 02期
关键词
3-dimensional endovaginal ultrasound; bulking agent injection; transurethral injection; periurethral distribution; STRESS URINARY-INCONTINENCE; MACROPLASTIQUE IMPLANTATION SYSTEM; INTRINSIC SPHINCTER DEFICIENCY; ENDOVAGINAL ULTRASOUND; INJECTION; MULTICENTER;
D O I
10.1097/SPV.0000000000000217
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objectives To use 3-dimensional endovaginal ultrasound to describe the location and distribution of bulking agent after an uncomplicated transurethral injection. Methods Endovaginal ultrasound was performed in 24 treatment-naive patients immediately after bulking agent was injected. The distance between the center of the hyperechoic density of bulking agent and the urethrovesical junction (UVJ) was measured in the sagittal and axial views. This was calculated in percentile length of urethra. Also, the pattern of tracking of bulking agent was assessed if it is presented. Results After the 2 subjects were excluded because of the poor quality of images, 22 patients were included in this study. Eighteen (82%) subjects showed 2 sites of bulking agents, and mostly, they were located around 3- and 9-o'clock positions. The average distance of bulking agent from left UVJ was at 16.9% of the length of the urethra (6.2 mm; range, 0.5-17 mm) and at 25.5% of the length of the urethra (8.9 mm; range, 0-24.8 mm) in the right side. The average length of urethra was 36.7 mm. Eleven of the 22 subjects (50%) had both sides within upper one third of urethra. The difference in distance between the 2 sides was less than 10 mm in 12 of 22 patients (54%). Nine of the 22 patients (41%) had a significant spread of bulking agent mostly either into the bladder neck or toward the distal urethra. Conclusions Although the bulking agent is most often found at 3- and 9-o'clock positions as intended, the distance from the UVJ is highly variable after an uncomplicated office-based transurethral injection. The bulking material does not form the characteristic spheres in 41% of cases and tracks toward the bladder neck or the distal urethra.
引用
收藏
页码:98 / 102
页数:5
相关论文
共 14 条
[1]  
Davila GW, 2011, ADV UROL, V2011, DOI 10.1155/2011/176498
[2]   Cross-Linked Polydimethylsiloxane Injection for Female Stress Urinary Incontinence: Results of a Multicenter, Randomized, Controlled, Single-Blind Study [J].
Ghoniem, Gamal ;
Corcos, Jacques ;
Comiter, Craig ;
Bernhard, Peter ;
Westney, O. Lenaine ;
Herschorn, Sender .
JOURNAL OF UROLOGY, 2009, 181 (01) :204-210
[3]  
Haylen BT, 2010, INT UROGYNECOL J, V21, P5, DOI [10.1007/s00192-009-0976-9, 10.1590/S1677-55382010000100032]
[4]   Three-dimensional endovaginal ultrasound examination following injection of Macroplastique for stress urinary incontinence: outcomes based on location and periurethral distribution of the bulking agent [J].
Hegde, Aparna ;
Smith, Aimee L. ;
Aguilar, Vivian C. ;
Davila, G. Willy .
INTERNATIONAL UROGYNECOLOGY JOURNAL, 2013, 24 (07) :1151-1159
[5]   Urethral Injection Therapy: What is the Mechanism of Action? [J].
Klarskov, Niels ;
Lose, Gunnar .
NEUROUROLOGY AND URODYNAMICS, 2008, 27 (08) :789-792
[6]   Transurethral injection of silicone microimplants for intrinsic urethral sphincter deficiency [J].
Koelbl, H ;
Saz, V ;
Doerfler, D ;
Haeusler, G ;
Sam, C ;
Hanzal, E .
OBSTETRICS AND GYNECOLOGY, 1998, 92 (03) :332-336
[7]   Pubovaginal sling versus transurethral Macroplastique for stress urinary incontinence and intrinsic sphincter deficiency:: a prospective randomised controlled trial [J].
Maher, CF ;
O'Reilly, BA ;
Dwyer, PL ;
Carey, MP ;
Cornish, A ;
Schluter, P .
BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2005, 112 (06) :797-801
[8]   Multicenter prospective randomized 52-week trial of calcium hydroxylapatite versus bovine dermal collagen for treatment of stress urinary incontinence [J].
Mayer, R. D. ;
Dmochowski, R. R. ;
Appell, R. A. ;
Sand, P. K. ;
Klimberg, I. W. ;
Jacoby, K. ;
Graham, C. W. ;
Snyder, J. A. ;
Nitti, V. W. ;
Winters, J. C. .
UROLOGY, 2007, 69 (05) :876-880
[9]   Macroplastique implantation system for female stress urinary incontinence: Long-term follow-up [J].
Nunes Tamanini, Jose Tadeu ;
Levi D'Ancona, Carlos Arturo ;
Netto, Nelson Rodrigues, Jr. .
JOURNAL OF ENDOUROLOGY, 2006, 20 (12) :1082-1086
[10]   Transurethral implantation of Macroplastiques® for the treatment of female stress urinary incontinence secondary to urethral sphincter deficiency [J].
Radley, SC ;
Chapple, CR ;
Mitsogiannis, IC ;
Glass, KS .
EUROPEAN UROLOGY, 2001, 39 (04) :383-389